In today's article we are going to talk about Flufenamic acid, a topic of great importance today. Flufenamic acid is a topic that has captured the attention of many people around the world, due to its relevance in different aspects of society. From its impact on the economy, politics, technology, culture, among others, Flufenamic acid has proven to be a topic that does not go unnoticed. In this article we will analyze different perspectives on Flufenamic acid, as well as its evolution over time and its influence on everyday life. Additionally, we will explore some concrete examples of how Flufenamic acid has changed the way we face various challenges in our daily lives. Without a doubt, Flufenamic acid is a topic that invites us to reflect and open our minds to new ideas and approaches. Don't miss this interesting article about Flufenamic acid!
Scientists led by Claude Winder from Parke-Davis invented FFA in 1963, along with fellow members of the class, mefenamic acid in 1961 and meclofenamic acid in 1964.: 718
Although flufenamic acid was at one time informally referred to as "Fluffy" (see history cache), this pet name could also refer to flufenoxine.
Structure
Flufenamic acid is a highly polymorphic drug molecule with multiple structurally characterized polymorphic modifications. It has a unique chemical structure and stands out among fenamates. Nowadays, eight polymorphic forms are known that are determined by different conformers, which makes flufenamic acid unique among other low-molecular medicinal compounds. A fundamental feature of the structure of flufenamic acid, which has generated significant interest in the design and development of drugs, is the presence of a trifluoromethyl group. Compounds with fluorine-containing substituents are known to have promising chemical and biological properties, since such groups often improve the pharmacokinetics and bioavailability of drugs. Studies have shown the promise of repositioning flufenamic acid and the use of drugs based on it in the treatment of Bartter syndrome.
Medical uses
Until recently, FFA was actively used in medical practice as an analgesic with anti-inflammatory and antipyretic effects. FFA has been proven effective in treating rheumatoid arthritis, osteoarthritis and other inflammation-related diseases. However, despite this, the use of FFA in the United States and other countries is limited since the compound causes frequent side effects. The rate of gastrointestinal side effects can be as high as 60%, manifested as at least one of the following: dyspepsia, nausea, abdominal pain and discomfort, constipation, diarrhoea, flatulence, indigestion, epigastric distress, stomatitits and anorexia. Besides gastrointestinal side effects, the drug can cause headache, dizziness and peripheral oedema.
Side effects
It is not widely used in humans as it has a high rate (30–60%) of gastrointestinal side effects. It is generally not available in the US. It is available in some Asian and European countries as a generic drug.
^ ab"Mefenamic Acid". LiverTox Database. U.S. National Institutes of Health (NIH). June 23, 2015. PMID31643176. Retrieved July 3, 2015. (fenamates generally not available in the United States, such as tolfenamic acid and flufenamic acid)
^Serezhkin VN, Savchenkov AV (June 3, 2015). "Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Crystal Structures of Flufenamic Acid—The Current Record-Holder of the Number of Structurally Studied Polymorphs". Crystal Growth & Design. 15 (6): 2878–2882. doi:10.1021/acs.cgd.5b00326. ISSN1528-7483. S2CID100245760.
^Mei H, Han J, White S, Graham DJ, Izawa K, Sato T, et al. (September 2020). "Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals". Chemistry. 26 (50): 11349–11390. doi:10.1002/chem.202000617. PMID32359086. S2CID218479815.
^Pippione AC, Carnovale IM, Bonanni D, Sini M, Goyal P, Marini E, et al. (April 2018). "Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid". European Journal of Medicinal Chemistry. 150: 930–945. doi:10.1016/j.ejmech.2018.03.040. hdl:10454/16082. PMID29602039. S2CID4690397.
^Nechipadappu SK, Tekuri V, Trivedi DR (May 2017). "Pharmaceutical Co-Crystal of Flufenamic Acid: Synthesis and Characterization of Two Novel Drug-Drug Co-Crystal". Journal of Pharmaceutical Sciences. 106 (5): 1384–1390. doi:10.1016/j.xphs.2017.01.033. PMID28185907.
^Maestrelli F, Rossi P, Paoli P, De Luca E, Mura P (February 2020). "The role of solid state properties on the dissolution performance of flufenamic acid". Journal of Pharmaceutical and Biomedical Analysis. 180: 113058. doi:10.1016/j.jpba.2019.113058. PMID31881398. S2CID209499101.